Story perspectives

FDA Approves Second Generic Mifepristone Amid Controversy

10/23/2025

Center

FDA Approves Mifepristone

The U.S. Food and Drug Administration approves Evita Solutions' second generic version of mifepristone.
Critics, including Republican attorneys general, argue the approval disregards adverse event data and call for a thorough review of Mifeprex.
U.S. Secretary Robert F. Kennedy Jr. defends the decision, citing legal obligations, but faces backlash for not suspending Mifeprex during the review.
The approval could lower prices and increase access, but opponents fear risks to women's health amid heightened tensions over reproductive rights.

Right

Paulin Advocates Psilocybin

A majority of Americans believes legalized marijuana worsened society, fueling concerns about New York's psilocybin legalization.
Assemblywoman Amy Paulin advocates medical use of psilocybin.
Critics warn of adverse effects and safety concerns for those with psychiatric disorders.
Hospitalizations related to hallucinogens increased 55% from 2016 to 2022.
Opponents urge lawmakers to reconsider current policies.

1 of 2

FDA Approves Mifepristone

The U.S. Food and Drug Administration approves Evita Solutions' second generic version of mifepristone.
Critics, including Republican attorneys general, argue the approval disregards adverse event data and call for a thorough review of Mifeprex.
U.S. Secretary Robert F. Kennedy Jr. defends the decision, citing legal obligations, but faces backlash for not suspending Mifeprex during the review.
The approval could lower prices and increase access, but opponents fear risks to women's health amid heightened tensions over reproductive rights.

1 / 2